Drugs / H002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05519293 | Dec 2022 → Feb 2025 | non-small cell lung carcinoma | RedCloud Bio | Unknown | No outcome recorded |
| Phase 1/2 | NCT05552781 | Aug 2022 → Feb 2025 | non-small cell lung carcinoma | RedCloud Bio | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05519293 ↗ |
| Modality | Small molecule | “Small molecule, Capsule” NCT05519293 ↗ |
| Route | Oral | “when given orally” NCT05519293 ↗ |